Find the latest pharmaceutical market place for formulations enquiry about Mesalazine on PharmaCompass.com.

Tender// Various Finished Dosage Formulations needed in Croatia [ENA17692]

Klinicki Bolnicki Centar Zagreb is looking for supplies of Various Finished Dosage Formulations for commercial purposes. The deadline is 13-Sept-2023.
1. Mesalazine (500 mg) Tablets. The required quantity is 45,202 units.
2. Morphine (10 mg) Tablets. The required quantity is 20,634 units.

Reply

28 Jul 2023

Tender// Various Finished Dosage Formulations needed in Poland [ENA16482]

Szpital Uniwersytecki W Krakowie is looking for supplies of Various Finished Dosage Formulations for commercial purposes. The deadline is 24-Mar-2023.
1. Mesalazine (500 mg) Tablets. The required quantity is 40,000 units.
2. Metoprolol Tartrate (50 mg) Tablets. The required quantity is 30,900 units.

Reply

27 Feb 2023

Tender// Various Finished Dosage Formulations needed in Poland [ENA16283]

Szpital Uniwersytecki W Krakow is looking for supplies of Various Finished Dosage Formulations for commercial purposes. The deadline is 27-Feb-2023.
1. Mesalazine (500 mg) Tablets. The required quantity is 12,500 units.
2. Prednisone (20 mg) Tablets. The required quantity is 4,200 units.

Reply

03 Feb 2023

Tender// Mesalazine (500 mg) Tablets needed in Bulgaria [ENA14026]

Specialized hospital for active treatment of children's diseases - Prof. Ivan Mitev EAD is looking for supplies of Mesalazine (500 mg) Gastro - Resistant Tablets for commercial purpose. The required quantity is 2,400 units. The deadline is 14-Jul-2022.

Reply

20 Jun 2022

Mesalazine (500 mg) Tablet or Capsule Dossier needed in Algeria [ENA11073]

A company that provides marketing, promotion and consulting services in hospital & retail markets focused on oncology, biotech products and rare diseases development is looking for suppliers of Mesalazine (500 mg) Tablet or Capsule Dossier for tech transfer.

Reply

09 Aug 2021

Mesalamine Tablets needed in Poland [ENA05981]

A company specialised in supplying of finished formulations, project management & product development is looking for suppliers of Mesalamine (400 mg, 500 mg, 800 mg and 1200 mg) tablets & the required quantity is 2-3 million tablets per annum.

Reply

07 Dec 2019

United_States_of_America Flag

Various FDFs needed for the US market [ENA02107]

A leading organisation that delivers regulatory affairs and quality assurance consulting and services for pharmaceutical products and natural healthcare products based in the United States is looking for suppliers of the following finished formulations:
1) Tolperisone HCl (150mg tablet)
2) Mesalazine (500mg tablet)
3) Betahistine (24mg tablet)
4) Alfuzosin (5mg and 10mg tablet)
5) Phloroglucinol (80/125mg tablet)
6) Alfa-amylase (3000U)
7) Josamycin (500mg tablet)
8) Nitroxinil (100mg tablet)

Reply

28 Sep 2018

Enquiry// Mesalazine sachets needed in Saudi Arabia [ENA01057]

A distribution company based in Saudi Arabia is looking for suppliers of Mesalazine sachets. The quantity required is: 4000 boxes from 60 sachets or equal 8000 boxes from 30 sachets. The manufacturers must not be based in Germany or India.

Reply

04 Jul 2018

Enquiry// Looking for In-licensing and tech transfer of Mesalazine 500 mg tablets dossiers in Algeria [ENA00764]

A modern and Quality oriented pharmaceutical company based in the City of Oran (Algeria) is looking for In-licensing and tech transfer of Mesalazine 500 mg tablets dossiers for a local marketing authorization local product manufacturing in Algeria. An EU approved dossier or an Indian dossier (dossier Audit to be performed) would be preferred. An EU GMP approved manufacturer is also preferred.

Reply

16 Mar 2018

Enquiry// Mesalazine modified release 500 mg tablets needed in Brazil [ENA00517]

Auramedi, a new Brazilian Pharma Company, an enterprise devoted to bringing to prescribers and customers new concepts related to treatment for health and well being is searching for suppliers of Mesalazine modified release 500 mg tablets for distribution in the country. The current requirement is for 3,000,000 to 5,000,000 tablets per year. The suppliers/manufacturers must support the product with following documents:
1. e-CTD format dossier
2. Certificate of Good Manufacture Practices issued by ANVISA
3. All the requirements to registration in ANVISA.
4. Price submission at CMED (Price Medication Chamber)
Interested suppliers should contact Edson Brito via Email: edson.brito@auramedi.com or Tel: +55 11 95116 8601.

Reply

14 Oct 2017

Enquiry// Looking for Marketing Partners for various Finished Dose Formulations in China [ENA00365]

Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners for its US FILED Products for the Chinese Market:

Products developed against international innovator:
1. Gliclazide 30/60 mg ER Tablets
2. Metformin HCl 500/750/1000 mg SR Tablets.
3. Lansoprazole 15/30 mg EC Capsules
4. Metoprolol 25/50/100/200 mg ER Tablets
5. Olmesartan Medoxomil 5/20/40 mg Tablets
6. Telmisartan 20/40/80 mg Tablets
7. Telmisartan + Hydrochlorthiazide 40/12.5, 80/12.5, 80/25 mg Tablets
8. Duloxetine 20/30/60 mg DR Capsules
9. Venlafaxine 37.5/75/150 mg SR Capsules
10. Darifenacin Hydrobromide 7.5/15 mg ER Tablets
11. Felodipine 2.5/5/10 mg ER Tablets
12. Rosuvastatin 5 /10/20/40 mg Tablets
13. Iloperidone 1/2/4/6/8/10/12 mg Tablets
14. Paliperidone 1.5/3/6/9 mg ER Tablets
15. Tolterodine Tartrate 2/4 mg ER Capsules

New Products Under development
1. Sitagliptin + Metformin 50/500 mg, 50/1000 mg Tablets
2. Sitagliptin + Metformin ER 50/500 mg, 50/1000; 100/1000 mg Tablets
3. Dapagliflozin 5/10 mg Tablets
4. Mesalamine 1.2 mg DR Tablets
5. Ezetimibe 10 mg Tablets
Interested partners can contact Sumeet Mehta at sumeet.mehta@inventiahealthcare.com or call +91-9930922062.

Reply

12 Jun 2017

EU CTD Dossiers Available // Looking for Marketing Partners in the EU for various products [ENA00142]

Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners in Europe for the following products which are at various stages of development -

Approved MA:
1. Duloxetine DR Capsules 30 mg/ 60 mg

Products Under development:
1. Gliclazide MR Tablets 30 mg/ 60 mg - EU fillable dossier will be ready by Oct 2017
2. Ezetimibe 10 mg Tablets - EU fillable dossier will be ready by Dec 2017

Products developed against international innovators and easily extendable to EU
1. Metformin SR Tablets 500 mg
2. Metformin SR Tablets 750 mg
3. Metformin SR Tablets 1000 mg
4. Darifenacin ER tablets 7.5 mg/ 15 mg

New Products Under development for EU
1. Rivaroxaban Tablets 10mg, 15 mg, 20 mg: will be ready by Q3 2019
2. Sitagliptin + Metformin: Target to be ready by Q2 2022
3. Mesalamine 1200 Gm Tablets - Target to be ready by Q3 2019

Interested partners should contact Priyanka Dhanjal at priyanka.dhanjal@inventiahealthcare.com or call +919987152274

Reply

02 Jan 2017

Enquiry//eCTD Dossiers required for various products [ENA00027]

Bilcare, a reliable and credible long-term partner of the global pharmaceutical industry for Clinical Trial Material Supplies has received requests for the following products -
1. Colesevalam tablets 625 mg for US market.
2. Nitrofurantoin capsules 50/ 100mg for UK, South Africa, Italy and Croatia markets
3. Cetirizine tablets 20 mg for Canada /Us/EU market
4. Colchicine tablets 0.5 mg for UK market
5. Carbimazole tablets 5 & 20 mg for UK market
6. Tolterodine ER capsule 2/4 mg for US market
7. Sevelamer Carbonate tablets 800 mg for US market
8. Sevelamer suspension for US
9. Carbidopa tablets for EU.
10. Azithromycin 250 mg capsules for EU
11. Mesalamine 1200 mg tabs for EU
12. Mesalazine 400 mg and 800 mg for EU
13. Alimemazine 10mg tab for EU
14. Hydrocortisone 10 mg tab for EU
15. Diclofenac sod.3%, sodium hyaluronate 2.5% (Solaraze) for EU
16. Ciprofibrate 100 mg tab for EU
17. Hydroxy urea capsules for US/EU
18. Tamoxifen citrate tabs for US/EU
19. Gefitinib tabs for US/EU
20. Sunitinib capsules for US/EU
21. Lacosamide for EU
22. Aripiprazole tabs for US
23. Darifenacin ER for US
24. Memantine tablets 5/10mg, Oral solution 2mg/ml, ER capsules 7/14/21/28mg for US,
25. Memantine ER + Donepezil capsules 14mg+10mg/ 28mg+10mg for US

Interested companies should respond immediately to Chhanda Das, VP-QA and Regulatory, Bilcare Limited at Chhanda.Das_GCS@bilcare.com.

Reply

04 Jul 2016

In-Licensing Request // Mesalamine 1200 mg Delayed Release tablets [EN00287]

Mesalamine 1200 mg Delayed Release tablets, a generic of Shire's LIALDA, are needed along with a CTD Dossier for the EU market. The request is from a global leader in clinical packaging supplies.

Reply

13 Feb 2016